Abstract 2070P
Background
Healthy lifestyle habits such as avoiding overweight, engaging in moderate physical activity for at least 150 minutes per week, and getting good quality sleep have not only been shown to decrease the incidence of certain cancers, but also have a clear impact on the outcome of patients diagnosed with breast cancer. Adherence to these recommendations has an impact on quality of life, and some studies suggest their beneficial effect on patient survival.
Methods
We included 181 patients diagnosed with breast cancer in different stages, Multivariable ambulatory circadian monitoring of skin temperature, motor activity, light exposure, and sleep patterns was performed for 7 consecutive days through a small watch-like device called Kronowise 3.0. The patients are divided into 3 groups: group 1 includes metastatic patients, group 2 consists of patients with early-stage breast cancer undergoing chemotherapy, and group 3 comprises patients with early-stage breast cancer under follow-up (more than 1 year after the completion of chemotherapy).
Results
The table describes the mean age with standard deviation, physical activity categorized as patients who achieve ≥ 150 minutes of moderate physical activity (MPA) per week, ≥ 300 minutes of moderate physical activity per week, ≥ 75 minutes of vigorous physical activity per week, patients with good sleep hygiene (between 7 and 9 hours of sleep per day), patients with < 10 hours of sedentary behavior, and the percentage of patients with overweight and obesity in each group. Table: 2070P
Median Age | MPA ≥ 150 min | MPA ≥ 300 min | Vigorous activity ≥ 75 min | Sedentariness < 10 hours | Median night sleep (hours) | Median BMI | BMI 25-30 | BMI ≥ 30 | |
GROUP 1 | 57 ± 9 | 65% | 45% | 4% | 90% | 7.5 | 25.53 | 21% | 20% |
GROUP 2 | 50 ± 7 | 88% | 73% | 15% | 100% | 6.7 | 23.26 | 15% | 5% |
GROUP 3 | 55 ± 10 | 89% | 79% | 20% | 100% | 6.5 | 26 | 20% | 17% |
Conclusions
Despite breast cancer patients not being sedentary and having higher levels of moderate physical activity compared to the general population, the occurrence of vigorous physical activity is quite low among these patients. It is imperative to establish proper sleep hygiene in these patients in order to improve parameters and reduce the rates of overweight and obesity, particularly among the metastatic population and long-term survivors, where these rates are significantly higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06